# Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

> **NCT04157985** · PHASE3 · COMPLETED · sponsor: **Dan Zandberg** · enrollment: 161 (actual)

## Conditions studied

- Advanced Solid Tumors
- NSCLC
- Bladder Cancer
- HNSCC
- Renal Cancer
- Melanoma
- Anal Cancer
- Colorectal Cancer
- Cholangiocarcinoma
- Gastric Cancer
- Hepatocellular Carcinoma
- Merkel Cell Carcinoma
- Cervical Cancer

## Interventions

- **DRUG:** Continue PD-1/PD-L1 Inhibitors treatment
- **OTHER:** Discontinue PD-1/PD-L1-1 inhibitor

## Key facts

- **NCT ID:** NCT04157985
- **Lead sponsor:** Dan Zandberg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2025-10-14
- **Final completion:** 2025-11-07
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157985, "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04157985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*